Skip to main content
Premium Trial:

Request an Annual Quote

George Poste, Michael Dunn, John Mendlein, William Hahne, Henri Lichenstein, Donna Morgan Murray, Richard Shimkets, Steven Henck, Elizabeth Whayland, Jeffry Brown

Premium

Orchid Biosciences Chairman George Poste was named director of the Arizona Biodesign Institute, Arizona State University’s new biodesign and biotechnology enterprise. Poste is also CEO of Health Technology Networks, a consulting group based in Scottsdale, Ariz. For six years ending in 1999, he was president for R&D and CSO and CTO at SmithKline Beecham.


Aclara Biosciences has hired Michael Dunn as chief business officer, a new position. Dunn, formerly executive VP of business development at Aurora, will be responsible for business development, sales, and marketing. Aclara also has appointed Affinium Pharmaceuticals CEO John Mendlein to its board of directors.


CuraGen has hired William Hahne as vice president of clinical development. Hahne comes to CuraGen from Eisai, where he was executive director and vice president of clinical research and development. Prior to Eisai, he worked at Glaxo.

The company has also promoted the following people:

Henri Lichenstein was named vice president of preclinical development. Lichenstein joined CuraGen in 1998 and most recently served as director of preclinical development.

Donna Morgan Murray was named vice president of regulatory affairs and project management. Murray joined CuraGen in 2000 as director of regulatory affairs and clinical development. Before joining CuraGen, Murray spent 15 years at Procter & Gamble Pharmaceuticals.

Richard Shimkets was named vice president of drug discovery. He joined CuraGen in 1996 and most recently served as director of drug discovery.

Steven Henck was named vice president of operations. Henck joined CuraGen in 1997, and most recently served as director of operations.

Elizabeth Whayland was named vice president of finance. Whayland, who joined CuraGen in 1994, was most recently director of financial management.


Applied DNA Sciences named to its board former BIO-Key CEO Jeffry Brown.

Filed under

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.